A Multicentre, Double-blind, Randomized, Placebo Controlled, Parallel Group, Phase 3, Safety Extension Study to Evaluate the Safety and Tolerability of Tezepelumab in Adults and Adolescents with Severe Uncontrolled Asthma (DESTINATION)
2022-06-27
عنوان الدراسة
A Multicentre, Double-blind, Randomized, Placebo Controlled, Parallel Group, Phase 3, Safety Extension Study to Evaluate the Safety and Tolerability of Tezepelumab in Adults and Adolescents with Severe Uncontrolled Asthma (DESTINATION)
داعم الدراسة
AstraZeneca
دواء الدراسة
Tezepelumab
رقم بروتوكول الدراسة
D5180C00018
حالة الدراسة
Ongoing
موقع الدراسة
KAUH-J
مرحلة الدراسة
3
评论与建议
如对政府服务有任何咨询或意见,请填写所需信息。